Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Zhao et al. identified lymphatic endothelial-like cells in glioblastoma and demonstrated their role in promoting tumour growth through increased glioblastoma cholesterol metabolism.
Although p53 was once considered undruggable, in this Review, Peuget et al. discuss the progress made in targeting p53 as a form of cancer therapy with approaches ranging from restoration of mutant p53 function to inhibition of the negative regulator of p53, MDM2, as well as newer strategies, including p53-based mRNA vaccines and antibodies.
In this Perspective, Cambria et al. propose that mechanical cues within the primary tumour that are known to promote metastasis imprint a persistent phenotype on cancer cells through mechanical memory to further facilitate cancer metastasis at distant sites.
In this Journal Club, Góss dos Santos discusses a study that successfully generated sarcoma-derived organoids and utilized them to identify a novel therapeutic target.
Transposable elements, also known as junk DNA, constitute nearly half of the human genome. This Review by Liang et al. discusses how tumours exploit these transposable elements during their evolution but also how they represent a vulnerability that could be targeted through immunotherapeutic approaches.
In a recent Developmental Cell paper, Falvo et al. establish a role for epigenetic memory of inflammatory injury in promoting pancreatic tumorigenesis.
In a comprehensive study in acute myeloid leukaemia, Ozga et al. demonstrate sex-specific differences in the frequency and prognostic effect of genetic alterations.
Although hyperactivation of BRAF has been well-established to drive tumour progression and drug resistance, the role of CRAF in cancer is becoming increasingly relevant. Here, Riaud et al. summarize the various oncogenic roles of CRAF and the potential for CRAF-targeted therapies to improve the clinical outcome for RAF1 altered tumours.
In this Review, Sato and colleagues provide an overview of the clinicopathological and phenotypical impact of lineage commitment and plasticity during tumorigenesis and progression of human epithelial cancer and discuss the molecular mechanisms that underlie histological lineage transition.
Epidemiologic cohorts of cancer have contributed to the current understanding of cancer risk factors. In this Comment, Gomez and Cheng advocate for a new generation of cohorts that include underserved and understudied populations, and also address the roles of structural and social determinants of health.
The concurrence of cancer and pregnancy can pose complex medical, psychosocial and ethical issues. In this Comment, Varella and Partridge present approaches to the treatment of cancer during pregnancy, with a focus on patient preferences, patient and fetal risks, and team-based management.
Kreuzaler et al. examine the spatial metabolic rewiring driven by oncogenic MYC and show that it leads to increased import of vitamin B5, which represents a metabolic vulnerability to tumour progression.
In this study, Bansaccal et al. analyse why, at some skin locations, oncogene-expressing cells rarely progress to cancer and found that a dense dermal collagen network prevents skin cancer formation.
In this Review, Mempel et al. use our understanding of the physiological response programmes of the immune system to the more commonplace challenges it encounters as a framework to interpret observations of chemokine function in tumours. When viewed in this way, the design of more effective therapeutic interventions leveraging the chemokine system to recalibrate response patterns to cancer might be possible.
In this Viewpoint article, we asked six scientists working in the field of cancer dormancy to provide their opinions on the current state of the field and the challenges associated with translating dormancy research into the clinic.
Numerous immunomodulatory antibodies for cancer treatment have been developed following the discovery of negative regulators of antitumour immunity such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4). The efficacy of these antibodies is determined not only by their ability to block or engage their target but also by their interactions with Fcγ receptors (FcγRs). This Review outlines our current knowledge of these interactions and discusses how we can use this knowledge to generate more effective cancer immunotherapies in the future.
In this Comment, Berna Özdemir summarizes the evidence for greater drug toxicity in female patients and emphasizes the need for increased awareness of sex differences at all stages of drug development to establish sex-specific anticancer treatment strategies.
Targeting platelets represents a promising approach to improve the therapeutic efficacy of chemotherapy and cancer immunotherapy. Here, Li and colleagues highlight the dynamic role of platelets in tumour development, progression, and response to therapy, and underscore the utility of tumour-educated platelets for precise tumour diagnosis and treatment.